A strategy for high-resolution protein identification in surface-enhanced laser desorption/ionization mass spectrometry: Calgranulin A and chaperonin 10 as protein markers for endometrial carcinoma

被引:27
作者
Guo, JZ
Yang, ECC
DeSouza, L
Diehl, G
Rodrigues, MJ
Romaschin, AD
Colgan, TJ
Siu, KWM
机构
[1] York Univ, Dept Chem, N York, ON M3J 1P3, Canada
[2] York Univ, Ctr Res Mass Spectrometry, N York, ON M3J 1P3, Canada
[3] York Univ, Dept Biol, N York, ON M3J 1P3, Canada
[4] Mt Sinai Hosp, Dept Biol, Toronto, ON M5G 1X5, Canada
[5] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[6] Toronto Gen Hosp, Toronto, ON, Canada
[7] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
关键词
endometrial carcinoma; nanobore liquid chromatography-tandem mass spectrometry; protein identification; surface-enhanced laser desorption/ionization-time of flight; tumor markers;
D O I
10.1002/pmic.200401059
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Surface-enhanced laser desorption/ionization-mass spectrometry (SELDI-MS) has conventionally been practiced on linear time of flight (TOF) which has low mass accuracy and resolution. Here we demonstrate in an examination of both malignant and nonmalignant endometrial tissue homogenates that high mass accuracy and resolution in the MS stage are crucial. Using a commercially available quadrupole/TOF (QqTOF), we were able to resolve two potential cancer markers, subsequently identified off-line as chaperonin 10 and calgranulin A, that differ by 8 Da in mass. Two off-line protein identification protocols were developed: the first was based on size-exclusion chromatography (SEC), sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), protein extraction, trypsin digestion, and matrix-assisted laser desorption/ionization-tandem MS (MALDI-MS/MS); the second on SEC and shotgun nano-liquid chromatography (nanoLC)-MS/MS. Analyses on a cohort of 44 endometrial homogenates showed 22 out of 23 nonmalignant samples had nondetectable to very low abundance of chaperonin 10 and calgranulin A; 17 of the 21 malignant samples had detectable to abundant levels of both proteins. Immunohistochemical staining of a tissue microarray of 32 samples showed that approximately half of malignant endometrial tissues exhibited positive staining for calgranulin A in the malignant epithelium, while 9 out of 10 benign tissues exhibited negative epithelial staining. In addition, macrophages/granulocytes in malignant as well as nonmalignant tissues showed positive staining. No immunostaining occurred in stroma or myometrium. Calgranulin A, in combination with chaperonin 10 and other proteins, may eventually constitute a panel of markers to permit diagnosis and screening of endometrial cancer.
引用
收藏
页码:1953 / 1966
页数:14
相关论文
共 66 条
[1]  
American Cancer Society, STAT
[2]   Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments [J].
Baggerly, KA ;
Morris, JS ;
Coombes, KR .
BIOINFORMATICS, 2004, 20 (05) :777-U710
[3]   Tamoxifen therapy for breast cancer and endometrial cancer risk [J].
Bernstein, L ;
Deapen, D ;
Cerhan, JR ;
Schwartz, SM ;
Liff, J ;
McGann-Maloney, E ;
Perlman, JA ;
Ford, L .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (19) :1654-1662
[4]   THE CALCIUM-BINDING PROTEINS MRP8 AND MRP14 FORM A MEMBRANE-ASSOCIATED HETERODIMER IN A SUBSET OF MONOCYTES MACROPHAGES PRESENT IN ACUTE BUT ABSENT IN CHRONIC INFLAMMATORY LESIONS [J].
BHARDWAJ, RS ;
ZOTZ, C ;
ZWADLOKLARWASSER, G ;
ROTH, J ;
GOEBELER, M ;
MAHNKE, K ;
FALK, M ;
MEINARDUSHAGER, G ;
SORG, C .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (07) :1891-1897
[5]   MRP 8/14 as marker for Plasmodium falciparum-induced malaria episodes in individuals in a holoendemic area [J].
Bordmann, G ;
Burmeister, G ;
Saladin, S ;
Urassa, H ;
Mwankyusye, S ;
Weiss, N .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1997, 4 (04) :435-439
[6]  
BRYANTGREENWOOD PK, 2000, MODERN PATHOL, V13, pA30
[7]  
Burkhardt K, 2001, J AM SOC NEPHROL, V12, P1947, DOI 10.1681/ASN.V1291947
[8]  
CHAN D, 2003, HUPO 2 ANN IUBIMB 19
[9]   Proteomics and cancer - Running before we can walk? [J].
Check, E .
NATURE, 2004, 429 (6991) :496-497
[10]   Clinical proteomics: Are we there yet? [J].
Cottingham, K .
ANALYTICAL CHEMISTRY, 2003, 75 (21) :472A-476A